Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.

Yafan YangHaomiao LiXiankai ChenJianjun QinYong LiYaxing ShenRuixiang ZhangXiaozheng KangZhen WangQingfeng ZhengPeng LuoYin LiJie He

Published in: Thoracic cancer (2023)

It appears to be feasible to add immunotherapy to nabTP regimen for locally advanced ESCC. Compared with TP, nabTP plus ICIs can achieve a better pCR rate in ESCC.

Keyphrases

rectal cancer
lymph node
squamous cell carcinoma
advanced non small cell lung cancer